BioNTech’s CEO ponders Omicron’s punch – but stays optimistic
Frankenfur –
BioNTech’s boss, Ugur Sahin, told Reuters that the current Covid‑19 shot probably stands up to Omicron, at least when it comes to severe disease that would require hospital care or ICU. In the next fortnight the company will run lab experiments on blood samples from folks who received either two or three doses of its Comirnaty vaccine. The goal? See whether antibodies in those samples can choke down Omicron and decide if a new vaccine is truly needed.
Key take‑aways from the CEO chat
- Severe disease protection? “We think it’s likely people will have substantial protection against severe disease caused by Omicron,” Sahin said. He specifically referenced hospital‑level or ICU cases.
- Mild/Moderate caveat. He expects the lab tests to show a bit of a drop in protection against milder cases, though the exact extent remains fuzzy.
- Boosters add an extra shield. A third dose, or booster, should give a “layer of protection” against all levels of Omicron infection, unlike just the standard two‑shot regimen.
- No panic mode. “There’s no reason to be particularly worried,” Sahin added. “The only thing that worries me at the moment is the fact that there are people that have not been vaccinated at all.”
In contrast: Moderna’s alarm bell
Moderna’s CEO, Stephane Bancel, has sounded a far more urgent note, warning of a “material drop” in protection from the existing shots. The two companies differ in tone, but both keep an eye on T‑cells – the immune system’s long‑term defenders that still see most of Omicron’s spike protein unchanged.
Where BioNTech is heading
- Fast‑track upgrades. BioNTech is already rushing to roll out a revamped version of its vaccine, which has already delivered over two billion doses worldwide. Whether that upgrade is necessary remains on the table.
- Regulatory momentum. The company’s working on a “pit‑stop” system that will let regulators jump the gun on new variants. They expect a market launch of 25–50 million doses within roughly 100 days, provided regulators sign off.
- Omicron dominance? Sahin stays level‑headed about whether Omicron will eclipse Delta. “Even if it does, that in itself is no reason to panic,” he said.
EU’s quick‑turn approach
The European drug regulator hinted it could approve Omicron‑specific vaccines in three to four months if required. Meanwhile, existing shots continue to cling to their protective edge.
So, what’s the moral of the story? BioNTech’s chief remains upbeat – current shots fend off the bad stuff, boosters give extra safety, and they’re all set to adapt as needed. The real worry: unvaccinated folks still playing the dangerous game. Stay safe!
